NasdaqGS - Nasdaq Real Time Price USD

Elevation Oncology, Inc. (ELEV)

3.6750 +0.0300 (+0.82%)
As of 12:54 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
40,338.0000
40,338.0000
94,549.0000
32,046.0000
17,276.0000
Operating Income
-40,338.0000
-40,338.0000
-94,549.0000
-32,046.0000
-17,276.0000
Other Income Expense
-5,336.0000
-5,336.0000
-506.0000
7.0000
11.0000
Pretax Income
-45,674.0000
-45,674.0000
-95,055.0000
-32,039.0000
-17,265.0000
Tax Provision
30.0000
30.0000
25.0000
--
--
Net Income Common Stockholders
-45,704.0000
-45,704.0000
-95,080.0000
-32,039.0000
-17,265.0000
Diluted NI Available to Com Stockholders
-45,704.0000
-45,704.0000
-95,080.0000
-32,039.0000
-17,265.0000
Basic EPS
-1.34
--
-4.09
-2.64
-1.04
Diluted EPS
-1.34
--
-4.09
-2.64
-1.04
Basic Average Shares
34,077.6750
--
23,267.1200
12,132.6100
16,536.7320
Diluted Average Shares
34,077.6750
--
23,267.1200
12,132.6100
16,536.7320
Total Operating Income as Reported
-45,445.0000
-45,445.0000
-94,549.0000
-32,046.0000
-17,276.0000
Total Expenses
40,338.0000
40,338.0000
94,549.0000
32,046.0000
17,276.0000
Net Income from Continuing & Discontinued Operation
-45,704.0000
-45,704.0000
-95,080.0000
-32,039.0000
-17,265.0000
Normalized Income
-41,669.4700
-41,669.4700
-95,080.0000
-32,039.0000
-17,265.0000
EBIT
-40,338.0000
-40,338.0000
-94,549.0000
-32,046.0000
-17,276.0000
EBITDA
-40,299.0000
-40,299.0000
-94,522.0000
-32,028.0000
-17,261.0000
Reconciled Depreciation
39.0000
39.0000
27.0000
18.0000
15.0000
Net Income from Continuing Operation Net Minority Interest
-45,704.0000
-45,704.0000
-95,080.0000
-32,039.0000
-17,265.0000
Total Unusual Items Excluding Goodwill
-5,107.0000
-5,107.0000
--
--
--
Total Unusual Items
-5,107.0000
-5,107.0000
--
--
--
Normalized EBITDA
-35,192.0000
-35,192.0000
-94,522.0000
-32,028.0000
-17,261.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
--
Tax Effect of Unusual Items
-1,072.4700
-1,072.4700
--
--
--
12/31/2020 - 6/25/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CLSD Clearside Biomedical, Inc.
1.3000
+3.17%
 
VINC Vincerx Pharma, Inc.
0.8166
-9.00%
 
INAB IN8bio, Inc.
0.9950
-4.33%
 
LPTX Leap Therapeutics, Inc.
3.1300
-1.26%
 
GUTS Fractyl Health, Inc.
6.66
-0.89%
 
JANX Janux Therapeutics, Inc.
48.06
+2.04%
 
BCAB BioAtla, Inc.
2.4000
+6.67%
 
ANNX Annexon, Inc.
4.6750
+1.85%
 
STRO Sutro Biopharma, Inc.
3.4700
+1.46%
 
TARA Protara Therapeutics, Inc.
2.9599
-2.95%